Aptamer Sciences Inc
291650
Company Profile
Business description
Aptamer Sciences Inc is a research and development based bio venture company. The company is focused on the Aptamer Technology Platform for the development of therapeutic and diagnostic platforms. It develops and facilitates drug development and other diagnostic products.
Contact
15, Pangyo-ro 228beongil
301, Building 3, Complex 1
Pangyo Seven Venture Valley
Bundang-gu, Gyeonggi-do
Seongnam-si13605
KORT: +82 317860317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
43
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
We think Netflix stock is moderately overvalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,172.50 | 12.40 | 0.14% |
| CAC 40 | 8,069.17 | 6.59 | 0.08% |
| DAX 40 | 24,560.98 | 142.14 | -0.58% |
| Dow JONES (US) | 49,077.23 | 588.64 | 1.21% |
| FTSE 100 | 10,138.09 | 11.31 | 0.11% |
| HKSE | 26,585.40 | 0.34 | 0.00% |
| NASDAQ | 23,224.82 | 270.50 | 1.18% |
| Nikkei 225 | 53,817.03 | 1,042.39 | 1.98% |
| NZX 50 Index | 13,556.87 | 139.70 | 1.04% |
| S&P 500 | 6,875.62 | 78.76 | 1.16% |
| S&P/ASX 200 | 8,848.70 | 12.80 | 0.14% |
| SSE Composite Index | 4,122.11 | 5.17 | 0.13% |